Gene therapy to cure HIV: Where to from here?

AIDS Patient Care and STDs

Volumn 30, Issue 12, 2016, Pages 531-533

  Johnston, Rowena ^a  

^a AmfAR ^*  (United States)

Author keywords

Cure; Gene therapy; HIV; In vivo targeting; Transduction efficiency

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5;

ACUTE MYELOBLASTIC LEUKEMIA; ADOPTIVE TRANSFER; ALLELE; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; GENE THERAPY; GERMANY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VIVO GENE TRANSFER; NONHUMAN; REVIEW; STEM CELL TRANSPLANTATION; GENETIC TRANSDUCTION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTATION;

GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; RECEPTORS, CCR5; TRANSDUCTION, GENETIC;

EID: 85002632505     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2016.0240     Document Type: Review

References (19)

1. Ananworanich J, Chomont N, Eller LA, et al. HIV DNA set point is rapidly established in acute HIV infection and dramatically reduced by early ART. EBioMedicine 2016; 11:68-72.
2. Markowitz M, Evering TH, Garmon D, et al. A randomized open-label study of 3- versus 5-drug combination anti-retroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr 2014;66:140-147.
3. Puertas MC, Massanella M, Llibre JM, et al. Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS 2014;28:325-334.
4. Deeks SG, Lewin SR, Ross AL, et al. International AIDS Society global scientific strategy: Towards an HIV cure 2016. Nat Med 2016;22:839-850.
5. Martinez-Picado J, Frost SD, Izquierdo N, et al. Viral evolution during structured treatment interruptions in chronically human immunodeficiency virus-infected individuals. J Virol 2002;76:12344-12348.
6. Strategies for Management of Antiretroviral Therapy Study Group, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
7. Pantaleo G, Levy Y. Therapeutic vaccines and immuno-logical intervention in HIV infection: A paradigm change. Curr Opin HIV AIDS 2016;11:576-584.
8. Sung JA, Lam S, Garrido C, et al. Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. J Infect Dis 2015;212:258-263.
9. Wagner T. Combining cell and gene therapy in an effort to eradicate HIV. AIDS Patient Care STDs 2016;30:534-538.
10. Kitchen SG, Zack JA. Engineering HIV-specific immunity with chimeric antigen receptors. AIDS Patient Care STDs 2016;30:556-561.
11. Caskey M, Klein F, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 2015;522:487-491.
12. National Cancer Institute. Nivolumab and Ipilimumab in Treating Patients with Advanced HIV Associated Solid Tumors. Available at: https://ClinicalTrials.gov/show/ NCT02408861; 2015 (Last accessed September 30, 2016).
13. Hutter G, Nowak D, Mossner M, et al. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 2009;360:692-698.
14. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PLoS Pathog 2013;9: e1003347.
15. Wang CX, Cannon PM. Clinical applications of genome editing to HIV cure. AIDS Patient Care STDs 2016;30: 539-544.
16. Symonds G, Bartlett JS, Kiem H-P, Tsie M, Breton L. Cell-delivered entry inhibitors for HIV-1: CCR5 downregula-tion and blocking virus/membrane fusion in defending the host cell population. AIDS Patient Care STDs 2016;30: 545-550.
17. Jerome KR. Disruption or excision of provirus as an approach to HIV cure. AIDS Patient Care STDs 2016;30:551-555.
18. Tebas P, Stein D, Tang WW, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med 2014;370:901-910.
19. Henrich TJ, Hanhauser E, Hu Z, et al. Viremic control and viral coreceptor usage in two HIV-1-infected persons ho-mozygous for CCR5 Delta32. AIDS 2015;29:867-876.